Freedom Investment Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,811
| Closed | -$40K | – | 805 |
|
|
2024
Q1 | $40K | Buy |
+15,811
| New | +$35.6K | ﹤0.01% | 776 |
|
|
2022
Q2 | – | Sell |
-5,261
| Closed | -$216K | – | 760 |
|
|
2022
Q1 | $216K | Sell |
5,261
-319
| -6% | -$14.1K | 0.02% | 713 |
|
|
2021
Q4 | $243K | Sell |
5,580
-166
| -3% | -$7.51K | 0.02% | 747 |
|
|
2021
Q3 | $288K | Sell |
5,746
-721
| -11% | -$43.7K | 0.02% | 647 |
|
|
2021
Q2 | $407K | Sell |
6,467
-2,920
| -31% | -$188K | 0.03% | 599 |
|
|
2021
Q1 | $872K | Sell |
9,387
-5,461
| -37% | -$559K | 0.07% | 345 |
|
|
2020
Q4 | $1.33M | Sell |
14,848
-11,092
| -43% | -$1.02M | 0.15% | 147 |
|
|
2020
Q3 | $2.68M | Sell |
25,940
-3,019
| -10% | -$325K | 0.29% | 74 |
|
|
2020
Q2 | $2.29M | Sell |
28,959
-3,698
| -11% | -$276K | 0.25% | 82 |
|
|
2020
Q1 | $2M | Buy |
32,657
+1,345
| +4% | +$77.5K | 0.18% | 122 |
|
|
2019
Q4 | $1.69M | Sell |
31,312
-3,451
| -10% | -$187K | 0.15% | 143 |
|
|
2019
Q3 | $1.82M | Sell |
34,763
-5,399
| -13% | -$252K | 0.16% | 131 |
|
|
2019
Q2 | $1.94M | Sell |
40,162
-3,179
| -7% | -$152K | 0.16% | 136 |
|
|
2019
Q1 | $2.19M | Sell |
43,341
-3,597
| -8% | -$212K | 0.18% | 124 |
|
|
2018
Q4 | $2.78M | Sell |
46,938
-12,830
| -21% | -$827K | 0.22% | 75 |
|
|
2018
Q3 | $3.65M | Buy |
59,768
+4,556
| +8% | +$266K | 0.23% | 69 |
|
|
2018
Q2 | $2.79M | Buy |
55,212
+4,601
| +9% | +$240K | 0.17% | 98 |
|
|
2018
Q1 | $2.67M | Buy |
50,611
+10,776
| +27% | +$537K | 0.14% | 112 |
|
|
2017
Q4 | $1.85M | Buy |
39,835
+2,894
| +8% | +$122K | 0.09% | 173 |
|
|
2017
Q3 | $1.49M | Sell |
36,941
-1,441
| -4% | -$52.1K | 0.08% | 206 |
|
|
2017
Q2 | $1.3M | Buy |
38,382
+271
| +0.7% | +$8.37K | 0.07% | 223 |
|
|
2017
Q1 | $1.11M | Sell |
38,111
-7,393
| -16% | -$225K | 0.06% | 260 |
|
|
2016
Q4 | $1.49M | Sell |
45,504
-6,256
| -12% | -$188K | 0.09% | 153 |
|
|
2016
Q3 | $1.63M | Sell |
51,760
-8,518
| -14% | -$248K | 0.1% | 131 |
|
|
2016
Q2 | $1.7M | Buy |
60,278
+7,528
| +14% | +$295K | 0.12% | 104 |
|
|
2016
Q1 | $1.92M | Sell |
52,750
-8,890
| -14% | -$314K | 0.14% | 88 |
|
|
2015
Q4 | $2.47M | Buy |
61,640
+57,251
| +1,304% | +$2M | 0.19% | 61 |
|
|
2015
Q3 | $316K | Sell |
4,389
-32,870
| -88% | -$1.08M | 0.03% | 455 |
|
|
2015
Q2 | $1.23M | Buy |
37,259
+10,184
| +38% | +$316K | 0.13% | 120 |
|
|
2015
Q1 | $779K | Buy |
27,075
+13,676
| +102% | +$392K | 0.09% | 189 |
|
|
2014
Q4 | $365K | Buy |
+13,399
| New | +$319K | 0.05% | 357 |
|
Other funds holding EBS
Freedom Investment Management's EBS Position: Q2 2024 in Review
Freedom Investment Management sold out of Emergent Biosolutions (EBS) in Q2 2024, closing a stake of 15,811 shares — an estimated $40K sold.
Freedom Investment Management first reported a position in EBS in Q4 2014 and held it in 31 quarters. The position peaked at $3.65M in Q3 2018. 141 funds tracked by Wall St. Rank hold EBS as of Q2 2024.
- Freedom Investment Management reported no remaining Emergent Biosolutions position as of Q2 2024 after selling out during the quarter.
- Freedom Investment Management sold 15,811 Emergent Biosolutions shares in Q2 2024, an estimated $40K.
- Freedom Investment Management first reported a position in Emergent Biosolutions in Q4 2014 and held it in 31 quarters.
- Freedom Investment Management's Emergent Biosolutions position peaked at $3.65M in Q3 2018.
- 141 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2024.
Based on Freedom Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.